Evaluating changes in the tumor environment in HER2-positive breast cancer patients
Tumor Microenvironment Alteration During Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer Patients
This study looks at how chemotherapy changes the tumor environment in patients with advanced HER2-positive breast cancer to better understand how the treatment works.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06533670 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess alterations in the tumor microenvironment of patients diagnosed with HER2-positive advanced breast cancer who are undergoing neoadjuvant chemotherapy followed by surgery. The study will monitor changes before, during, and after treatment to better understand the effects of chemotherapy on tumor characteristics. By focusing on patients with clinical T stage II-IV and no distant metastases, the research seeks to provide insights into the effectiveness of curative treatment approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients over 18 years old with HER2-positive breast cancer undergoing curative neoadjuvant chemotherapy.
Not a fit: Patients with significant comorbidities that may interfere with study results may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies for HER2-positive breast cancer by providing insights into how chemotherapy affects the tumor microenvironment.
How similar studies have performed: While there have been studies examining the tumor microenvironment in breast cancer, this specific focus on HER2-positive patients undergoing neoadjuvant chemotherapy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria i. Adult patients over 18 years of age ii. Patients undergoing curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast cancer patients Exclusion criteria If you have other comorbidities that, according to the researcher's judgment, may affect the results of the study
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Study coordinator: Wonshik Han, Ph.D
- Email: hanw@snu.ac.kr
- Phone: +82-2-2072-1958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.